Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study.

Autor: Rosas J; Rheumatology Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain. Electronic address: j.rosas.gs@gmail.com., Liaño FP; Internal Medicine Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain., Cantó ML; Pneumology Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain., Barea JMC; Intensive Care Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain., Beser AR; Pharmacy Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain., Rabasa JTA; Internal Medicine Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain., Adsuar FM; Anesthesia Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain., Auli BV; Pneumology Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain., López IF; Intensive Care Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain., Sainz AMG; Internal Medicine Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain., Ramis PE; Internal Medicine Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain., Pérez LR; Intensive Care Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain., Rebollo MLN; Intensive Care Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain., Lorido RH; Neurology Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain., Escolar LG; Gastroenterology Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain.
Jazyk: English; Spanish; Castilian
Zdroj: Reumatologia clinica [Reumatol Clin (Engl Ed)] 2020 Nov 28. Date of Electronic Publication: 2020 Nov 28.
DOI: 10.1016/j.reuma.2020.10.009
Abstrakt: Objective: To describe the experience of treatment with baricitinib (BARI) and/or tocilizumab (TCZ), in monotherapy or combined, in patients admitted for interstitial pneumonia secondary to COVID19, and for 30 days after discharge.
Methods: Medical records of patients admitted with COVID19 and IP with PaO 2 /FiO 2 <300, treated with BARI and/or TCZ, and compared with patients who did not, were retrospectively reviewed.
Results: Sixty patients were included; 43 (72%) are males, mean age 67 (SD: 14) years (<50 years: 17%; 51-70: 30%; >70: 53%), with 8.5 (SD: 1) days of symptoms. Sixteen (27%) patients required ICU (94% in <70 years). Fifteen (25%) patients died, 67% in >70 years; 11 (18%) patients died in the first 15 days of admission and 4 (7%) between days 16 to 30. Twenty-three (38%) patients received BARI, 12 (52%) monotherapy (Group 1), during 6 (SD: 2.6) days on average, none required ICU and 2 (17%) died. Thirty-one (52%) patients received TCZ, 20 (33%) as monotherapy (Group 2), 16 (52%) patients required ICU and 4 (20%) died. In the 11 (18%) patients who received BARI (2.8 [SD: 2.5] days average) and TCZ combined (Group 3), 3 (27%) required ICU and died. There were no severe side effects in BARI or TCZ patients. In the 17 (28%) patients who received neither BARI nor TCZ (Group 4), none required ICU and 6 (35%) died. Mean (SD) PaO 2 /FiO 2 at admission between groups was respectively: 167 (82.3), 221 (114.9), 236 (82.3), 276 (83.2).
Conclusion: Treatment with BARI and TCZ did not cause serious side effects. They could be considered early in patients with NI secondary to COVID19 and impaired PaO2/PaFi.
(Copyright © 2020. Publicado por Elsevier España, S.L.U.)
Databáze: MEDLINE
Externí odkaz: